Skip to main content
. 2022 Nov 16;13:7013. doi: 10.1038/s41467-022-34629-3

Fig. 5. cAMP production and competition binding assays using PACAP27, VIP and chimeric peptides Ala4-PACAP27 and Gly4-VIP.

Fig. 5

Pharmacological characterization of PACAP27 (black), VIP (turquoise) and the chimeric peptides Ala4-PACAP27 (pink) and Gly4-VIP (purple); (a) VPAC1R cAMP production, (b) PAC1R cAMP production and (c) PAC1R competition binding. a, b Left, Concentration–response curves for cAMP production normalized to % PACAP27 response (data are the mean ± SEM from 5 independent experiments); right, pEC50 determined from each individual experiment are shown with mean ± SEM of the 5 independent experiments also shown. c Left, Competition binding measured using nanoBRET with AF568-conjugated PACAP27 probe (30 nM) and Nluc-PAC1R in the absence and presence of competing peptides. Data are normalized to % specific PACAP27-AF568 nanoBRET signal (data are the mean ± SEM from 5 independent experiments); right, pIC50 values determined from each individual experiment are displayed with mean ± SEM of the data shown. pEC50 and pIC50 data analysed using one-way ANOVA, Tukey’s post-hoc (ns = not significant, *p < 0.05, **p < 0.01, ****<0.0001). Source data are provided in the Source Data file.